search
Back to results

Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery (PREPACOL2)

Primary Purpose

Rectal Cancer Surgery

Status
Recruiting
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Sennosides colonic preparation
Oral Gentamycin
Oral Ornidazole
Oral Placebo Gentamycin
Oral Placebo Ornidazole
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Rectal Cancer Surgery focused on measuring Mechanical Bowel Preparation (MBP), Oral antibiotics, Rectal cancer surgery, Surgical site infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged 18 or more
  • Scheduled to undergo elective restorative laparoscopic cancer of the rectal (<15 cm from the anal margin) with sphincter preservation
  • With Signed consent
  • And affiliated to the French social security system

Exclusion Criteria:

  • Emergent surgery
  • Scheduled total colo-proctectomy
  • Scheduled abdominoperineal restion with definitive colostomy
  • Scheduled associated concomitant resection of another organ (liver, etc.)
  • Active bacterial infection at the time of surgery or recent antibiotic therapy (up to 15 days before surgery)
  • Associated inflammatory bowel disease
  • Patients with known colonization with multidrug-resistant enterobacteriacea
  • History of allergy or contraindication to the Ornidazole, Gentamycin, X-PREP or to any of the excipients of the drugs used.
  • Cirrhosis of grade B and C (Child-Pugh classification)
  • Myasthenia
  • Allergy to one of the other treatments administered for the purpose of the trial (including betadine)
  • Patient suffering from severe central neurologic diseases, fixed or progressive.
  • Pregnant patients
  • Refusal to participate or inability to provide informed consent

Sites / Locations

  • Service de chirurgie Colorectale / Hôpital BeaujonRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1) " MBP and oral antibiotics " group

2) " MBP alone " group

Arm Description

Sennosides colonic preparation Oral Gentamycin Oral Ornidazole

Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole

Outcomes

Primary Outcome Measures

Postoperative 30-day surgical site infection (SSI).
SSI will be defined and classified as superficial, deep and/or organ-space infection on the basis of validated and well-defined criteria developed by the Centers for Disease Control and Prevention (CDC), validated in French by the Comité technique des infections nosocomiales et des infections liées aux soins.

Secondary Outcome Measures

Overall postoperative morbidity
Including all postoperative complications occurring within 30 days after surgery, defined and classified according to the Clavien-Dindo classification.
Severe postoperative morbidity
Including all complications graded 3 or more according to the Clavien-Dindo classification, and occurring within 30 days after surgery.
Postoperative mortality
Including all deaths occurring within 30 days after surgery.
Postoperative anastomotic leakage
Defined as the passing of any intra-colonic content (air, liquid, intestinal content, or radiological contrast) through an anastomosis or by an peri-anastomotic abscess, even in the absence of intra-colonic content leak through the anastomosis, observed in drainages, surgical incision, vagina, during a surgical procedure or on a radiological examination, occurring within 90 days after surgery.
Postoperative length of hospital stay
Calculated from the day of surgery to the day of hospital discharge.
Unplanned hospitalization
Defined as any unplanned hospitalization between surgery and postoperative day 90.
Tolerance of the colonic preparation
Evaluated using a dedicated questionnaire performed the evening before surgery.
Clostridium difficile colitis occurrence
Defined as clinical symptoms of clostridium difficile colitis with at least 1 stool sample positive for Clostridium difficile toxin A/B as detected by enzyme-linked immunosorbent assay within 30 days after surgery.
Rate of multi-resistant bacteria carriage
Defined as rate of multi-resistant bacteria carriage
Date of adjuvant chemotherapy beginning
If indicated
Temporary stoma closure rate
Define as temporary stoma closure

Full Information

First Posted
March 9, 2018
Last Updated
May 12, 2022
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT03491540
Brief Title
Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery
Acronym
PREPACOL2
Official Title
Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery: a Multi Center Double-Blinded Randomized Controlled Trial (PREPACOL2 Study)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 3, 2018 (Actual)
Primary Completion Date
May 31, 2023 (Anticipated)
Study Completion Date
August 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone Our hypothesis is that a preoperative colonic preparation including a combination of mechanical bowel preparation and oral antibiotics before elective laparoscopic rectal cancer surgery is associated with a reduced rate of 30-day postoperative surgical site infection, as compared to mechanical bowel preparation alone
Detailed Description
This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone. This study's hypothesis is that a preoperative colonic preparation including a combination of mechanical bowel preparation and oral antibiotics before elective laparoscopic rectal cancer surgery is associated with a reduced rate of 30-day postoperative surgical site infection, as compared to mechanical bowel preparation alone Preoperative mechanical bowel preparation (MBP) has been proposed in an attempt to reduce the colonic fecal load and to limit the risk of surgical site contamination, thus theoretically limiting the risk of postoperative surgical site infection (SSI). However, the benefit of such MBP before colorectal surgery is related to type of procedure performed. Indeed, several randomized controlled trials (RCT) and meta-analyses have demonstrated the absence of benefit of MBP before colon cancer surgery, whereas a recent RCT suggested that MBP before rectal cancer surgery was associated to a significant reduction of postoperative SSI, as compare to the absence of preoperative MBP. Recent studies suggested that the adjunction of oral antibiotics during MBP could help efficiently reduce the risk of postoperative SSI. Indeed, a recent meta-analysis of RCT have suggested that patients preoperatively receiving both MBP and oral antibiotics were exposed to a significantly reduced risk of postoperative SSI, as compared to patients receiving only preoperative MBP. This result was confirmed in a recent RCT which compared preoperative MBP and oral antibiotics versus MBP alone in a heterogeneous population of patients who underwent laparoscopic colonic or rectal surgery. However, to date, no RCT compared the outcomes of an MBP with oral antibiotics to MBP without oral antibiotics in a homogeneous cohort of patients undergoing rectal cancer surgery. This study aims to demonstrate that a preoperative combination of mechanical bowel preparation and oral antibiotics, before elective laparoscopic rectal cancer surgery, is associated with a reduction of postoperative surgical site infection rate, as compared to mechanical bowel preparation alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Cancer Surgery
Keywords
Mechanical Bowel Preparation (MBP), Oral antibiotics, Rectal cancer surgery, Surgical site infection

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Both participants and investigators are unaware of the intervention assignment
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1) " MBP and oral antibiotics " group
Arm Type
Experimental
Arm Description
Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
Arm Title
2) " MBP alone " group
Arm Type
Placebo Comparator
Arm Description
Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
Intervention Type
Drug
Intervention Name(s)
Sennosides colonic preparation
Intervention Description
Mechanical bowel preparation : Sennosides colonic preparation (X-PREP) 1 per day, on day -2 and day -1
Intervention Type
Drug
Intervention Name(s)
Oral Gentamycin
Intervention Description
Oral gentamycin: Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
Intervention Type
Drug
Intervention Name(s)
Oral Ornidazole
Intervention Description
Oral ornidazole : Ornidazole 1 g per day (2 tablet per day), on day -2 and day -1; In tablets
Intervention Type
Drug
Intervention Name(s)
Oral Placebo Gentamycin
Intervention Description
Placebo for oral gentamycin : Same presentation as oral gentamycin x4 per day on day -2 and day -1
Intervention Type
Drug
Intervention Name(s)
Oral Placebo Ornidazole
Intervention Description
Placebo for oral ornidazole : Same presentation as oral ornidazole 1g per day (2 tablets per day) on day -2 and day -1
Primary Outcome Measure Information:
Title
Postoperative 30-day surgical site infection (SSI).
Description
SSI will be defined and classified as superficial, deep and/or organ-space infection on the basis of validated and well-defined criteria developed by the Centers for Disease Control and Prevention (CDC), validated in French by the Comité technique des infections nosocomiales et des infections liées aux soins.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Overall postoperative morbidity
Description
Including all postoperative complications occurring within 30 days after surgery, defined and classified according to the Clavien-Dindo classification.
Time Frame
30 days
Title
Severe postoperative morbidity
Description
Including all complications graded 3 or more according to the Clavien-Dindo classification, and occurring within 30 days after surgery.
Time Frame
30 days
Title
Postoperative mortality
Description
Including all deaths occurring within 30 days after surgery.
Time Frame
30 days
Title
Postoperative anastomotic leakage
Description
Defined as the passing of any intra-colonic content (air, liquid, intestinal content, or radiological contrast) through an anastomosis or by an peri-anastomotic abscess, even in the absence of intra-colonic content leak through the anastomosis, observed in drainages, surgical incision, vagina, during a surgical procedure or on a radiological examination, occurring within 90 days after surgery.
Time Frame
90 days
Title
Postoperative length of hospital stay
Description
Calculated from the day of surgery to the day of hospital discharge.
Time Frame
Up to 90 days
Title
Unplanned hospitalization
Description
Defined as any unplanned hospitalization between surgery and postoperative day 90.
Time Frame
90 days
Title
Tolerance of the colonic preparation
Description
Evaluated using a dedicated questionnaire performed the evening before surgery.
Time Frame
The day before surgery
Title
Clostridium difficile colitis occurrence
Description
Defined as clinical symptoms of clostridium difficile colitis with at least 1 stool sample positive for Clostridium difficile toxin A/B as detected by enzyme-linked immunosorbent assay within 30 days after surgery.
Time Frame
30 days
Title
Rate of multi-resistant bacteria carriage
Description
Defined as rate of multi-resistant bacteria carriage
Time Frame
The day before or the day of surgery
Title
Date of adjuvant chemotherapy beginning
Description
If indicated
Time Frame
90 days
Title
Temporary stoma closure rate
Description
Define as temporary stoma closure
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 18 or more Scheduled to undergo elective restorative laparoscopic cancer of the rectal (<15 cm from the anal margin) with sphincter preservation With Signed consent And affiliated to the French social security system Exclusion Criteria: Emergent surgery Scheduled total colo-proctectomy Scheduled abdominoperineal restion with definitive colostomy Scheduled associated concomitant resection of another organ (liver, etc.) Active bacterial infection at the time of surgery or recent antibiotic therapy (up to 15 days before surgery) Associated inflammatory bowel disease Patients with known colonization with multidrug-resistant enterobacteriacea History of allergy or contraindication to the Ornidazole, Gentamycin, X-PREP or to any of the excipients of the drugs used. Cirrhosis of grade B and C (Child-Pugh classification) Myasthenia Allergy to one of the other treatments administered for the purpose of the trial (including betadine) Patient suffering from severe central neurologic diseases, fixed or progressive. Pregnant patients Refusal to participate or inability to provide informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yves PANIS, MD, phd
Phone
33 (0)1 40 87 45 47
Email
yves.panis@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Massimo GIACCA, MD
Email
massimo.giacca@aphp.fr
Facility Information:
Facility Name
Service de chirurgie Colorectale / Hôpital Beaujon
City
Clichy
State/Province
Ile De France
ZIP/Postal Code
92110
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yves PANIS, MD, Phd
Phone
33 (0)1 40 87 45 47
Email
yves.panis@aphp.fr
First Name & Middle Initial & Last Name & Degree
Massimo GIACCA, MD,PhD
Email
massimo.giacca@aphp.fr

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is not a plan to make IPD available.

Learn more about this trial

Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery

We'll reach out to this number within 24 hrs